Skip to main content

Main menu

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
    • COVID-19 articles
    • Obituary notices
  • Authors & Reviewers
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
    • Open access
    • Patient engagement
  • Physicians & Subscribers
    • Benefits for Canadian physicians
    • CPD Credits for CMA Members
    • Subscribe to CMAJ Print
    • Subscription prices
    • Obituary notices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2023
    • Avis de décès
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Instagram
  • Listen to CMAJ podcasts
Practice

Campylobacter and bacterial gastroenteritis

Eleni Galanis
CMAJ September 11, 2007 177 (6) 570-571; DOI: https://doi.org/10.1503/cmaj.070660
Eleni Galanis MD MPH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Responses
  • Metrics
  • PDF
Loading
  • © 2007 Canadian Medical Association

Campylobacter is the most common cause of bacterial gastroenteritis in the developed world.1 In Canada, where the disease is reportable, 9345 cases (30.2 per 100 000) of campylobacteriosis were reported in 2004, as compared with 4953 cases of salmonellosis (16.0 per 100 000).2 Reported cases represent only a fraction of the actual number. The highest rates are observed among children less than 5 years old and young adults, particularly men, aged 20–29 years (Box 1).2 The rates of Campylobacter infection have been declining in Canada and in many developed countries in the last 5–10 years.2 The reasons for this are not clear, but they may be due to improvements in food safety.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Box 1.

In developing countries, the disease is mostly confined to young children owing to early exposure to contaminated drinking water and close contact with farm animals.1 Campylobacter is one of the most common causes of diarrhea in Canadian travellers to developing countries.1

Symptoms occur 1–10 days after exposure. Illness is characterized by diarrhea, which may be bloody, abdominal pain, which may be severe and may mimic appendicitis, fever and, rarely, vomiting.1 Some patients may be asymptomatic. Illness usually resolves within 2–5 days but may last up to several weeks. Post-infectious complications such as reactive arthritis and Guillain–Barré syndrome occur in about 1% and 0.1% of infections, respectively.1 About 5%–10% of patients require admission to hospital, and 5 in 10 000 die.

Because the clinical presentation is similar to that caused by other bacterial enteric pathogens, diagnosis of campylobacteriosis is not possible on the basis of symptoms alone. It is done through isolation of Campylobacter in stool specimens with the use of selective media.

Treatment is usually supportive. Antibiotic treatment can be considered if the patient has severe or prolonged symptoms. The drugs of choice include erythromycin and azithromycin. Ciprofloxacin resistance increased in human Campylobacter isolates after the licensure of fluoroquinolones for use in farm animals internationally.1 Although fluoroquinolones are no longer used in poultry in Canada, resistance levels remain relatively high.

Campylobacter leads mostly to sporadic infections. About 50% of cases are associated with the handling and consumption of poultry. Other causes include the consumption of beef, pork, raw milk and contaminated water and contact with pets and farm animals.1 Outbreaks have been reported infrequently and most have been associated with contaminated drinking water, such as the outbreak of infection from Escherichia coli O157:H7 and Campylobacter in Walkerton, Ont., in 2000. Outbreaks have also occurred among men who have sex with men.

In Canada, about 95% of cases are caused by Campylobacter jejuni, 4% by Campylobacter coli and 1% by other Campylobacter species. C. jejuni is primarily isolated from poultry but also from cattle, sheep, goats, pets and wildlife. C. coli is most often isolated from swine. Drinking water can become contaminated by animal waste.

It is unclear why the rates of campylobacteriosis are higher than those of other types of bacterial gastroenteritis. Campylobacter infection spreads very easily among poultry at the farm level; poultry are believed to act as an amplifier of Campylobacter. Up to 90% of poultry flocks are colonized in some European countries.1 In British Columbia, during the summers of 2005 and 2006, 41%–59% of flocks were infected with Campylobacter, as compared with 12%–14% with Salmonella (Dr. Jane Pritchard, BC Ministry of Agriculture and Lands: personal communication, 2007). In Canada, 37%–51% of retail chicken has been found to be contaminated with Campylobacter, as compared with only 10%–17% with Salmonella.3

Infection control measures need to be taken along the farm-to-fork continuum (Box 2). At the farm level, biosecurity measures help decrease transmission between animals and between flocks and herds. During slaughter, good hygiene and the separation of infected from noninfected animals decrease the risk of cross-contamination. In some Scandinavian countries, strict poultry farm and processing measures have been implemented, and a decline in human Campylobacter infection rates has subsequently been observed.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint

Box 2.

In the kitchen, care should be taken to avoid direct and indirect (through common utensils and surfaces) contact between raw meat and other uncooked foods and to cook poultry and meat thoroughly. Food handlers should be excluded from work while symptomatic. Travellers should avoid raw milk and dairy products, eat only well-cooked meat and drink boiled or bottled water. Everyone should wash their hands after contact with raw meats and animals.

In summary, Campylobacter infection should be suspected in a patient with acute diarrhea and severe abdominal pain. A cluster of cases of campylobacteriosis or the suspicion that a patient drank contaminated water should be reported immediately to the local public health unit for investigation. The most effective way individuals can prevent Campylobacter infection is to drink treated water and pasteurized milk, adequately cook meats and avoid cross-contamination of foods in the kitchen.

Footnotes

  • This article has been peer reviewed.

    Competing interests: None declared.

REFERENCES

  1. 1.↵
    Nachamkin I, Blaser MJ, eds. Campylobacter. 2nd ed. Washington: ASM Press; 2000.
  2. 2.↵
    Notifiable diseases online. Ottawa: Public Health Agency of Canada. Available: http://dsol-smed.phac-aspc.gc.ca/dsol-smed/ndis/index_e.html(accessed 2007 May 3).
  3. 3.↵
    Canadian Integrated Program for Antimicrobial Resistance Surveillance. Recovery rate and final number of isolates submitted for antimicrobial resistance (AMR) testing across the bacterial species, the active surveillance components and the animal species, 2002–2005. Ottawa: Public Health Agency of Canada. Available: www.phac-aspc.gc.ca/cipars-picra/pdf/cipars-picra-2005_pr-t1_e.pdf (accessed 2007 May 8).
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 177 (6)
CMAJ
Vol. 177, Issue 6
11 Sep 2007
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Campylobacter and bacterial gastroenteritis
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Campylobacter and bacterial gastroenteritis
Eleni Galanis
CMAJ Sep 2007, 177 (6) 570-571; DOI: 10.1503/cmaj.070660

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Campylobacter and bacterial gastroenteritis
Eleni Galanis
CMAJ Sep 2007, 177 (6) 570-571; DOI: 10.1503/cmaj.070660
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
    • Footnotes
    • REFERENCES
  • Figures & Tables
  • Responses
  • Metrics
  • PDF

Related Articles

  • Highlights of this issue
  • Dans ce numéro
  • PubMed
  • Google Scholar

Cited By...

  • Comparative analysis of L-fucose utilization and its impact on growth and survival of Campylobacter isolates
  • Draft Genome Sequences of Nine Campylobacter hyointestinalis subsp. lawsonii Strains
  • Development and Validation of a Comparative Genomic Fingerprinting Method for High-Resolution Genotyping of Campylobacter jejuni
  • L-Fucose utilization provides Campylobacter jejuni with a competitive advantage
  • Google Scholar

More in this TOC Section

  • SARS-CoV-2 vaccination in pregnancy
  • Infantile perianal pyramidal protrusion
  • Topical nonsteroidal anti-inflammatory drugs
Show more Practice

Similar Articles

Collections

  • Topics
    • Infectious diseases

 

View Latest Classified Ads

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • CPD credits
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Advisory Panels
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions
CMAJ Group

Copyright 2023, CMA Impact Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of these resources in an accessible format, please contact us at CMAJ Group, 500-1410 Blair Towers Place, Ottawa ON, K1J 9B9; p: 1-888-855-2555; e: [email protected]

CMA Civility, Accessibility, Privacy

 

Powered by HighWire